11th Global Drug Delivery & Formulation Summit

Upperton will be exhibiting the DDF Summit in Berlin from Monday 9th to Wednesday 11th March, at stand 5. Attending DDF on behalf of Upperton are: Dr Richard Johnson the Founder & CEO and Klara Fisken the Marketing & Communications Officer.

We are looking forward to meeting both new and existing clients on our stand. So if you have an API which requires formulation development or clinical manufacture, please contact us to book an appointment or alternatively drop by our exhibition stand to talk to Upperton’s team

Upperton's Team

Richard Johnson
Founder and CEO

Dr Richard Johnson founded Upperton Pharma Solutions in August 1999, and continues to play a key role in the management and strategic development of the company. With over 30 years of experience in the pharmaceutical, biotechnology and drug delivery fields, Richard previously held senior management positions at Andaris Limited (Vectura) and Delta Biotechnology (now Albumedix). Richard holds an honours degree in Biology from University of York and a Ph.D. from the University of Warwick and has a proven track record in successfully developing innovative pharmaceutical products from early feasibility studies through to commercial products.

Klara Fisken
Marketing & Communications Officer

Klara Fisken joined Upperton in August 2018, after completing a three month project at Upperton which was part of her MSc in Applied Biopharmaceutical Biotechnology and Entrepreneurship from the University of Nottingham. Klara is responsible for Upperton’s marketing which includes newsletters, creating marketing materials, press releases, website and social media. 

Recent News at Upperton

Upperton have been investing in new equipment to enhance our capabilities in manufacturing final dosage forms. Our current focus is in enhancing / increasing out put in our tabletting capabilities. In 2019 Upperton acquired a new cutting edge tablet press, Futorque X by KG-Pharma which can produce up to 130,000 tablets per hour or supporting D0E and research studies with minimal material. 

The O Hara LC M5 coater was also purchased in 2019; film coating is a key process offering a wide range of drug delivery benefits including: taste/odour masking, stability protection, modification of release profiles, ease of administration and product identification. Upperton will follow these investments through the purchase of further tabletting equipment.

The new service UpperSolv was launched in late 2019. UpperSolv™ is a signposted pathway to rapid, tailored screening of small quantities of API, the manufacture of prototype formulations using a range of scalable enabling technologies and comparison of the biopharmaceutical performance via a PK assessment.

The DDF Summit

The Global Drug Delivery & Formulation (DDF) Summit provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines. Covering topics such as: research opportunities and challenges, personalised therapies, analytical techniques, 3D priniting, multivariate analysis techniques, pharmaceutical development, oral delivery of biologics and many more.